Companies › Shanghai Vitalgen BioPharma
3 active drug programs in 5 registered trials: 3 Phase 1, 1 Phase 2, 1 Phase 3; Metabolic and endocrine, Neurology, Ophthalmology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| VGR-R01 CYP4V2-coding gene delivered by AAV vector | CYP4V2 | Phase 3 | Bietti Crystalline Dystrophy | Dec 2026 |
| VGN-R09b Gene therapy delivering AADC gene to putamen | AADC | Phase 2 | Aromatic L-amino Acid Decarboxylase Deficiency; Parkinson's Disease | Sep 2030 |
| VGM-R02b rAAV9-mediated GCDH gene replacement therapy | GCDH | Phase 1 | Glutaric Acidemia Type I | Aug 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06699108 | VGR-R01 | Phase 3 | Bietti Crystalline Dystrophy | Ophthalmology | Dec 2026 |
| NCT06217861 | VGM-R02b | Phase 1 | Glutaric Acidemia Type I | Metabolic and endocrine | Aug 2027 |
| NCT05694598 | VGR-R01 | Phase 1 | Bietti Crystalline Dystrophy | Ophthalmology | Sep 2028 |
| NCT06480461 | VGN-R09b | Phase 1 | Parkinson's Disease | Neurology | Sep 2030 |
| NCT06432140 | VGN-R09b | Phase 2 | Aromatic L-amino Acid Decarboxylase Deficiency | Metabolic and endocrine | Sep 2030 |
Amylyx Pharmaceuticals Innovent Biologics Technology Limited (Shanghai R&D Center) Beijing Suncadia Pharmaceuticals Rhythm Pharmaceuticals BioMarin Pharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.